Patent intelligence · US
US 9839688
Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer
Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer
Patent details — US 9839688
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 12, 2017
- Expiration
- Dec 7, 2037
- Applicant
- Provectus Pharmatech, Inc.
- Claims
- 26
- CPC classes
- A61K, A61K2039/505, A61K31/352, A61K31/365
Quick answer
US 9839688 (Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer) is held by Provectus Pharmatech, Inc.. Status: granted. Granted Dec 12, 2017. Expires Dec 7, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Provectus Pharmatech, Inc.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K2039/505, A61K31/352, A61K31/365, A61K38/193, A61K38/20
More from Provectus Pharmatech, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12377068
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
granted -
US 12133840
Halogenated xanthene composition and method for treating hematologic cancers
granted -
US 12064507
Composition and method for oral treatment of leukemia
granted -
US 11974980
In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
granted -
US 11975106
Uses of halogenated xanthenes in oncology and virology
granted -
US 11938182
Halogenated xanthenes as vaccine adjuvants
granted -
US 11426379
Combination of local and systemic therapies for enhanced treatment of dermatologic conditions
granted -
US 11419844
Halogenated xanthene composition and method for treating hematologic cancers
granted
Frequently asked questions
What is US patent 9839688?
US 9839688 (Combination of rose bengal and systemic immunomodulative therapies for enhanced treatment of cancer) is held by Provectus Pharmatech, Inc.. Status: granted. Granted Dec 12, 2017. Expires Dec 7, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9839688?
Provectus Pharmatech, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 29 pharmaceutical patents for this assignee.
When does US 9839688 expire?
Our index shows an expiration date of Dec 7, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.